Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?

Published Date: 02 Feb 2024

Pembrolizumab improves OS, while nivolumab as a single agent has no effect on DFS.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New study reveals racial disparities in breast cancer diagnosis and outcomes in Canada

2.

New therapeutic strategies raised to prevent and resist metastasis in lymph nodes of breast cancer

3.

Chronic stress and obesity work together to accelerate pancreatic cancer development and growth, study finds

4.

Study finds 1 in 12 patients labeled as having 'benign' results actually had high-risk prostate cancer

5.

Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot